SOMERSET, N.J. and NEW YORK, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Catalent (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, and BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced an agreement for the manufacture of NurOwn, BrainStorms autologous cellular therapy being investigated for the treatment of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease or motor neuron disease.
NurOwn induces mesenchymal stem cells (MSCs) to secrete high levels of neurotrophic factors (NTFs) known to promote the survival of neurons and neuroprotection. The therapy has received Fast Track status from the U.S. FDA for ALS and has also been granted Orphan Drug Status for ALS by both the FDA and the European Medicines Agency. BrainStorm is currently completing a 200-patient, double-blind, placebo-controlled, repeat-dosing NurOwn Phase 3 study in the U.S.
As part of its commitment, Catalent will undertake the transfer of the manufacturing process to, and provide future CGMP clinical supply of NurOwn from, its new, 32,000 square-foot cell therapy manufacturing facility in Houston, Texas. On completion of the clinical trials and in anticipation of potential approval of NurOwn, the companies will look to extend the partnership to include commercial supply from the Houston facility.
We are proud to have a partner in Catalent whose excellence in manufacturing quality therapies will support commercial supply of NurOwn, said Chaim Lebovits, Chief Executive Officer of BrainStorm Cell Therapeutics. We know that ALS patients are in urgent need of a new treatment option. If NurOwn is successful in the current clinical trials, this agreement will be integral to ensuring rapid access for patients.
Manja Boerman, Ph.D., President, Catalent Cell & Gene Therapy, said, Our experience in cell therapy development, and the manufacturing capabilities that our newly constructed, state-of-the-art facility in Houston offers, position us to best support BrainStorm, with its leading therapeutic candidate for ALS treatment. We look forward to partnering with BrainStorm and providing our stem cell manufacturing expertise as we work to optimize production and streamline the products path towards commercial launch.
About Catalent Cell & Gene Therapy
With deep experience in viral vector scale-up and production, Catalent Cell & Gene Therapy is a full-service partner for adeno-associated virus (AAV) and lentiviral vectors, and CAR-T immunotherapies. When it acquired MaSTherCell, Catalent added expertise in autologous and allogeneic cell therapy development and manufacturing to position it as a premier technology, development and manufacturing partner for innovators across the entire field of advanced biotherapeutics. Catalent has a global cell and gene therapy network of dedicated, large-scale clinical and commercial manufacturing facilities, and fill-finish and packaging capabilities located in both the U.S. and Europe. An experienced partner, Catalent Cell & Gene Therapy has worked with industry leaders across 70+ clinical and commercial programs.
About Catalent
Catalent is the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. With over 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable global clinical and commercial product supply. Catalent employs approximately 14,000 people, including around 2,400 scientists and technicians, at more than 45 facilities, and in fiscal year 2020 generated over $3 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit http://www.catalent.com
More products. Better treatments. Reliably supplied.
About NurOwn
NurOwn (autologous MSC-NTF) cells represent a promising investigational therapeutic approach to targeting disease pathways important in neurodegenerative disorders. MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo. MSCs are converted into MSC-NTF cells by growing them under patented conditions that induce the cells to secrete high levels of neurotrophic factors. Autologous MSC-NTF cells can effectively deliver multiple NTFs and immunomodulatory cytokines directly to the site of damage to elicit a desired biological effect and ultimately slow or stabilize disease progression. BrainStorm has fully enrolled a Phase 3 pivotal trial of autologous MSC-NTF cells for the treatment of amyotrophic lateral sclerosis (ALS). BrainStorm also received U.S. FDA acceptance to initiate a Phase 2 open-label multicenter trial in progressive MS and enrollment began in March 2019.
About BrainStorm Cell Therapeutics Inc.
BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The Company holds the rights to clinical development and commercialization of the NurOwn technology platform used to produce autologous MSC-NTF cells through an exclusive, worldwide licensing agreement. Autologous MSC-NTF cells have received Orphan Drug status designation from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of amyotrophic lateral sclerosis (ALS). BrainStorm has fully enrolled a Phase 3 pivotal trial in ALS (NCT03280056), investigating repeat-administration of autologous MSC-NTF cells at six U.S. sites supported by a grant from the California Institute for Regenerative Medicine (CIRM CLIN2-0989). The pivotal study is intended to support a filing for U.S. FDA approval of autologous MSC-NTF cells in ALS. BrainStorm also recently received U.S. FDA clearance to initiate a Phase 2 open-label multicenter trial in progressive multiple sclerosis (MS). The Phase 2 study of autologous MSC-NTF cells in patients with progressive MS (NCT03799718) completed enrollment inAugust 2020. For more information, visit the company's website at http://www.brainstorm-cell.com.
Safe-Harbor Statement
Statements in this announcement other than historical data and information, including statements regarding future clinical trial enrollment and data, constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may", "should", "would", "could", "will", "expect", "likely", "believe", "plan", "estimate", "predict", "potential", and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, BrainStorm's need to raise additional capital, BrainStorm's ability to continue as a going concern, regulatory approval of BrainStorm's NurOwn treatment candidate, the success of BrainStorm's product development programs and research, regulatory and personnel issues, development of a global market for our services, the ability to secure and maintain research institutions to conduct our clinical trials, the ability to generate significant revenue, the ability of BrainStorm's NurOwn treatment candidate to achieve broad acceptance as a treatment option for ALS or other neurodegenerative diseases, BrainStorm's ability to manufacture and commercialize the NurOwn treatment candidate, obtaining patents that provide meaningful protection, competition and market developments, BrainStorm's ability to protect our intellectual property from infringement by third parties, heath reform legislation, demand for our services, currency exchange rates and product liability claims and litigation,; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available athttp://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.
Media Contacts:
Read more from the original source:
Catalent and BrainStorm Cell Therapeutics Announce Partnership for the Manufacture of Mesenchymal Stem Cell Platform Therapy NurOwn - GlobeNewswire
- 2013 New Jersey Stem Cell Research Symposium [Last Updated On: August 22nd, 2014] [Originally Added On: August 22nd, 2014]
- Stem Cells and Cloning - New Jersey Right to Life | Prolife [Last Updated On: August 22nd, 2014] [Originally Added On: August 22nd, 2014]
- Regenexx Stem Cell Procedures - New York and New Jersey ... [Last Updated On: August 22nd, 2014] [Originally Added On: August 22nd, 2014]
- Wise Young, M.D., Ph.D., Announced as 12th New Jersey Symposium on Biomaterials Science Dinner Speaker [Last Updated On: September 4th, 2014] [Originally Added On: September 4th, 2014]
- Stem cell medicine - Worldnews.com [Last Updated On: September 6th, 2014] [Originally Added On: September 6th, 2014]
- Stem Cell Therapy Spine and Joint Bergen County New Jersey [Last Updated On: September 27th, 2014] [Originally Added On: September 27th, 2014]
- Sarah heads to Russia in latest battle in war on MS [Last Updated On: October 5th, 2014] [Originally Added On: October 5th, 2014]
- Frequently Asked Questions [FAQs] - Stem Cell Therapy New ... [Last Updated On: October 27th, 2014] [Originally Added On: October 27th, 2014]
- Targeting cancer stem cells: a new therapy to cure cancer ... [Last Updated On: October 29th, 2014] [Originally Added On: October 29th, 2014]
- Dynamic Imaging System Nets Yale Scientist the 2014 STEM CELLS Young Investigator Award [Last Updated On: December 4th, 2014] [Originally Added On: December 4th, 2014]
- A Few Cells Could Prevent Bone Marrow Transplant Infections [Last Updated On: February 3rd, 2015] [Originally Added On: February 3rd, 2015]
- Stem Cells from Placenta Show Promise for Treating Heart Failure [Last Updated On: February 12th, 2015] [Originally Added On: February 12th, 2015]
- New Jersey Commission Science and Technology Grants - Stem ... [Last Updated On: February 13th, 2015] [Originally Added On: February 13th, 2015]
- FDA Expands Indication for REVLIMID (Lenalidomide) in Combination with Dexamethasone to Include Patients Newly ... [Last Updated On: February 18th, 2015] [Originally Added On: February 18th, 2015]
- ADDING MULTIMEDIA FDA Expands Indication for REVLIMID (Lenalidomide) in Combination with Dexamethasone to Include ... [Last Updated On: February 19th, 2015] [Originally Added On: February 19th, 2015]
- EAT A PEACH | Beneficial Bacteria [Last Updated On: April 7th, 2015] [Originally Added On: April 7th, 2015]
- Orthopedic Stem Cell Solutions at the Spine & Pain Center ... [Last Updated On: May 8th, 2015] [Originally Added On: May 8th, 2015]
- Research at Rutgers | Rutgers University [Last Updated On: October 19th, 2015] [Originally Added On: October 19th, 2015]
- Research Overview | Rutgers Cancer Institute of New Jersey [Last Updated On: October 19th, 2015] [Originally Added On: October 19th, 2015]
- The New Jersey Cord Blood Bank (NJCBB) [Last Updated On: October 19th, 2015] [Originally Added On: October 19th, 2015]
- NJMS Stem Cells - Rutgers New Jersey Medical School [Last Updated On: August 1st, 2016] [Originally Added On: August 1st, 2016]
- New York and New Jersey - Stem Cell Therapy & Platelet ... [Last Updated On: August 1st, 2016] [Originally Added On: August 1st, 2016]
- New results on stem cells ageing - CODIF Recherche et ... [Last Updated On: August 1st, 2016] [Originally Added On: August 1st, 2016]
- Basic Science FAQs - Stem Cell Institute of New Jersey [Last Updated On: October 29th, 2016] [Originally Added On: October 29th, 2016]
- Stem Cell - New Jersey Catholic Conference - Trenton, NJ [Last Updated On: November 23rd, 2016] [Originally Added On: November 23rd, 2016]
- Non-Surgical - The New Jersey Orthopaedic Institute [Last Updated On: November 27th, 2016] [Originally Added On: November 27th, 2016]
- Blood Drive To Honor 2 1/2-year-old Brain Tumor Patient, 4-year-old Lymphoma Patient - TAPinto.net [Last Updated On: July 6th, 2017] [Originally Added On: July 6th, 2017]
- WCT selected to conduct Ph III NurOwn Trial in ALS - OutSourcing-Pharma.com [Last Updated On: July 6th, 2017] [Originally Added On: July 6th, 2017]
- FDA OKs Pfizer drug for rare, fast-killing type of leukemia - New Jersey Herald [Last Updated On: August 24th, 2017] [Originally Added On: August 24th, 2017]
- Celularity, Inc., Accelerates Breakthrough Placental Discovery & Therapeutic Platform - TASS [Last Updated On: August 24th, 2017] [Originally Added On: August 24th, 2017]
- Stem Cell Center Of NJ - New Jersey Stem Cell Therapy [Last Updated On: August 24th, 2017] [Originally Added On: August 24th, 2017]
- Blood Donations Needed During Labor Day Holiday Season - TAPinto.net [Last Updated On: August 29th, 2017] [Originally Added On: August 29th, 2017]
- Taconic, Silverstein to build 150000 s/f life science research center - Real Estate Weekly [Last Updated On: August 29th, 2017] [Originally Added On: August 29th, 2017]
- Blood Donations Needed During Labor Day Holiday Season - TAPinto - TAPinto.net [Last Updated On: August 29th, 2017] [Originally Added On: August 29th, 2017]
- Lab-made "mini organs" helping doctors treat cystic fibrosis - New Jersey Herald [Last Updated On: August 29th, 2017] [Originally Added On: August 29th, 2017]
- Blood Donations Needed Pre and Post Labor Day Holiday - East ... - TAPinto.net [Last Updated On: August 29th, 2017] [Originally Added On: August 29th, 2017]
- National Stem Cell Centers | Stem Cell Therapy in New York ... [Last Updated On: June 20th, 2018] [Originally Added On: June 20th, 2018]
- Regenexx Stem Cell Procedures - New York and New Jersey Metro [Last Updated On: July 15th, 2018] [Originally Added On: July 15th, 2018]
- New York & New Jersey - Stem Cell Therapy & Platelet Rich ... [Last Updated On: July 24th, 2018] [Originally Added On: July 24th, 2018]
- FAQ - Stem Cell Center Of NJ - New Jersey Stem Cell Therapy [Last Updated On: July 29th, 2018] [Originally Added On: July 29th, 2018]
- New Jersey Regenerative Medicine Stem Cell and PRP ... [Last Updated On: September 16th, 2018] [Originally Added On: September 16th, 2018]
- Stem Cells and Cloning | New Jersey Right to Life [Last Updated On: September 16th, 2018] [Originally Added On: September 16th, 2018]
- Cord Blood Storage, NY and NJ | Community Blood Services [Last Updated On: September 20th, 2018] [Originally Added On: September 20th, 2018]
- Stem Cell Therapy in New Jersey | National Stem Cell Centers [Last Updated On: November 13th, 2018] [Originally Added On: November 13th, 2018]
- Do Stem Cells Really Work? - New Jersey Stem Cell Therapy [Last Updated On: December 19th, 2018] [Originally Added On: December 19th, 2018]
- Obtain Stem Cell Therapy in New Jersey - Stem Cell Miami [Last Updated On: February 23rd, 2019] [Originally Added On: February 23rd, 2019]
- PTC Therapeutics Inc. (PTCT) and MacroGenics Inc. (NASDAQ:MGNX) Comparing side by side - MS Wkly [Last Updated On: October 14th, 2019] [Originally Added On: October 14th, 2019]
- Reviewing PTC Therapeutics Inc. (PTCT)'s and Inovio Pharmaceuticals Inc. (NASDAQ:INO)'s results - MS Wkly [Last Updated On: October 14th, 2019] [Originally Added On: October 14th, 2019]
- Comparing of Osmotica Pharmaceuticals plc (OSMT) and VistaGen Therapeutics Inc. (NASDAQ:VTGN) - MS Wkly [Last Updated On: October 14th, 2019] [Originally Added On: October 14th, 2019]
- Reviewing Morphic Holding Inc. (MORF)'s and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI)'s results - MS Wkly [Last Updated On: October 14th, 2019] [Originally Added On: October 14th, 2019]
- Reviewing Curis Inc. (CRIS)'s and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI)'s results - MS Wkly [Last Updated On: October 14th, 2019] [Originally Added On: October 14th, 2019]
- Comparing of NewLink Genetics Corporation (NLNK) and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) - MS Wkly [Last Updated On: October 14th, 2019] [Originally Added On: October 14th, 2019]
- Comparison of Merus N.V. (MRUS) and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) - MS Wkly [Last Updated On: October 14th, 2019] [Originally Added On: October 14th, 2019]
- Reviewing ImmunoGen Inc. (IMGN)'s and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI)'s results - MS Wkly [Last Updated On: November 2nd, 2019] [Originally Added On: November 2nd, 2019]
- On Stage: Allegaeon ready to rock Philly - The Unionville Times [Last Updated On: November 2nd, 2019] [Originally Added On: November 2nd, 2019]
- Reviewing Brainstorm Cell Therapeutics Inc. (BCLI)'s and Pieris Pharmaceuticals Inc. (NASDAQ:PIRS)'s results - MS Wkly [Last Updated On: November 2nd, 2019] [Originally Added On: November 2nd, 2019]
- Contrasting of Brainstorm Cell Therapeutics Inc. (BCLI) and HOOKIPA Pharma Inc. (NASDAQ:HOOK) - MS Wkly [Last Updated On: November 2nd, 2019] [Originally Added On: November 2nd, 2019]
- PTC Therapeutics Inc. (PTCT) and Jounce Therapeutics Inc. (NASDAQ:JNCE) Comparing side by side - FinanceMercury [Last Updated On: November 6th, 2019] [Originally Added On: November 6th, 2019]
- Live Cell Imaging Consumables Market Evolving to a Next-Generation Strategy with New Partnerships, Technologies and Targets by 2023 key players LCC... [Last Updated On: November 6th, 2019] [Originally Added On: November 6th, 2019]
- Contrasting of Spero Therapeutics Inc. (SPRO) and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) - FinanceMercury [Last Updated On: November 6th, 2019] [Originally Added On: November 6th, 2019]
- Reviewing Capricor Therapeutics Inc. (CAPR)'s and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI)'s results - FinanceMercury [Last Updated On: November 6th, 2019] [Originally Added On: November 6th, 2019]
- Reviewing Surface Oncology Inc. (SURF)'s and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI)'s results - FinanceMercury [Last Updated On: November 6th, 2019] [Originally Added On: November 6th, 2019]
- Reviewing Magenta Therapeutics Inc. (MGTA)'s and PTC Therapeutics Inc. (NASDAQ:PTCT)'s results - FinanceMercury [Last Updated On: November 6th, 2019] [Originally Added On: November 6th, 2019]
- Celgene to Present New and Updated Data on Key Hematology Pipeline Therapies at American Society of Hematology (ASH) 2019 Annual Meeting - Business... [Last Updated On: November 6th, 2019] [Originally Added On: November 6th, 2019]
- Comparing of Rigel Pharmaceuticals Inc. (RIGL) and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) - The Broch Herald [Last Updated On: November 28th, 2019] [Originally Added On: November 28th, 2019]
- Weekly pick of Neuroscience news from around the world - Brain Tumour Research [Last Updated On: November 30th, 2019] [Originally Added On: November 30th, 2019]
- Stemming the Tide Confronting Anti-Semitism in the 21st Century - The Times of Israel [Last Updated On: January 5th, 2020] [Originally Added On: January 5th, 2020]
- Reviewing Phibro Animal Health (NASDAQ:PAHC) & AgeX Therapeutics (NASDAQ:AGE) - Riverton Roll [Last Updated On: January 15th, 2020] [Originally Added On: January 15th, 2020]
- Horizon to provide access to novel base editing technology - SelectScience [Last Updated On: January 15th, 2020] [Originally Added On: January 15th, 2020]
- John Theurer Cancer Center Announces Appointment of Five New Physicians - Newswise [Last Updated On: January 15th, 2020] [Originally Added On: January 15th, 2020]
- Horizon Discovery to Provide Access to Novel Base Editing Technology - Yahoo Finance [Last Updated On: January 15th, 2020] [Originally Added On: January 15th, 2020]
- Europe's guardian of stem cells and hopes, real and unrealistic - FRANCE 24 [Last Updated On: January 20th, 2020] [Originally Added On: January 20th, 2020]
- TV Guy: A return to history with Auschwitz Untold - New Jersey Herald [Last Updated On: January 27th, 2020] [Originally Added On: January 27th, 2020]
- Musicians and community coming together in Asbury Park to help Point Pleasant 3-year old - Asbury Park Press [Last Updated On: February 12th, 2020] [Originally Added On: February 12th, 2020]
- Are stem cells really the key to making humans live longer? - Wired.co.uk [Last Updated On: February 16th, 2020] [Originally Added On: February 16th, 2020]
- SpaceX set to launch Falcon 9 rocket and Dragon capsule from Cape Canaveral this week - Florida Today [Last Updated On: March 4th, 2020] [Originally Added On: March 4th, 2020]
- CO2 Incubators Market Update: Uncover the Business Strategies of Leaders & Laggards of the Market - 3rd Watch News [Last Updated On: March 6th, 2020] [Originally Added On: March 6th, 2020]
- Genmab Announces U.S. FDA Approval of Subcutaneous Formulation of Daratumumab, DARZALEX FASPRO (daratumumab and hyaluronidase-fihj), for the Treatment... [Last Updated On: May 6th, 2020] [Originally Added On: May 6th, 2020]
- Hitachi Chemical Advanced Therapeutics Solutions and apceth Biopharma GmbH Enter into Strategic Clinical and Commercial Manufacturing Agreements with... [Last Updated On: May 13th, 2020] [Originally Added On: May 13th, 2020]
- CO2 Incubators Market is Expected to Witness a Steady Growth by 2025 - Farmers Ledger [Last Updated On: June 4th, 2020] [Originally Added On: June 4th, 2020]